AML是最常见的成人白血病类型之一，FLT3-ITD是最常见FLT3突变类型。3期试验中，与化疗相比，quizartinib方案将死亡风险降低22.4%，有潜力改变新诊FLT3-ITD ...

为探讨 AML 非强化治疗中出现可靶向克隆时的策略、MRD 检测应用等问题，研究人员分析相关疗法及生存数据。发现 Ven-Aza 序贯治疗或三联疗法可优化方案，MRD 检测仍需完善，AML 生存率显著提升。研究为临床提供方向。 急性髓系白血病（acute myeloid leukemia ...

2021年2月，Xospata(适加坦，吉瑞替尼)获国家药监局批准，治疗FLT3突变急性髓系白血病（AML）。 2021年03月31日讯 /生物谷BIOON ...

研究题目：#28 Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) 研究背景：CPX-351已获批用于治疗既往骨髓增生异常综合征(MDS ...

这篇综述聚焦急性髓系白血病（AML）治疗难题。探讨白血病干细胞（LSCs）、炎症、免疫功能障碍等因素对治疗的阻碍，如 LSCs 的耐药性、缺乏特异性标记，以及免疫微环境的不良影响，为攻克 AML 治疗困境提供思路。 引言 急性髓系白血病（AML）是一种极具异质 ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.

The importance of the eight newly defined somatic mutations for AML pathogenesis is not yet known, and will require functional validation studies in tissue culture cells and mouse models to assess ...

Panelists emphasize that patients with KMT2A-rearranged acute myeloid leukemia (AML) often face steep educational challenges at diagnosis, requiring clear communication about the subtype’s ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies. Prof. Wang concludes by ...

it is above all the perturbation of the RUNX1 gene -- a gene that regulates many other genes -- that seems to be responsible for AML pathogenesis. Targeting the perturbed regulator could pave the ...